Drug Sponsors

BioLineRx acquires Agalimmune to accelerate immuno-oncology pipeline

Thursday, March 23, 2017

BioLineRx, a clinical-stage biopharmaceutical company focused on oncology and immunology, has acquired Agalimmune, a private U.K.-based company with an innovative, anti-cancer immunotherapy platform. Acquisition consideration consisted of a $6 million upfront payment, of which $3 million is in cash and the remainder in BioLineRx shares. Additional future payments may be made based on development and commercial milestones.

[Read More]

Califf launches People-Centered Clinical Research Foundation

Wednesday, March 22, 2017

Dr. Robert Califf has launched the People-Centered Clinical Research Foundation (PCRF), a new nonprofit organization committed to accelerating people-driven research. PCRF has been created to sustain and expand a national network for clinical research that originated with funding from the Patient-Centered Outcomes Research Institute (PCORI) and studies conducted by the National Patient-Centered Clinical Research Network (PCORnet).

[Read More]

Boston Biomedical Associates creates Boston Biomedical Associates Limited Tel Aviv

Wednesday, March 15, 2017

Boston Biomedical Associates (BBA), a clinical research and consulting company based in Marlborough, Massachusetts, has announced the opening of an affiliate office, Boston Biomedical Associates Limited (BBA Ltd.) in Tel Aviv, Israel. Tami Abudi and Adi Richter have been named co-chief executive officers of Boston Biomedical Associates Limited. Abudi also serves as the director of Clinical Development and Adi Richter as the director of Legal Affairs.

[Read More]

Virta Health launches in the Bay Area with $37M

Monday, March 13, 2017

Virta Health, a new company founded by a team of physicians, scientists and technologists trained at Stanford, MIT and Harvard, launched with a bold mission to reverse type 2 diabetes—a chronic, progressive condition that affects more than 29 million Americans and 415 million people globally. The company’s debut comes on the heels of a new peer-reviewed study that demonstrates Virta was successful in reversing type 2 diabetes in half of its clinical trial patients and eliminating or reducing insulin in 87% of patients in just 10 weeks.

[Read More]

Apotex to develop new R&D and manufacturing center

Thursday, March 9, 2017

Apotex, a Canadian owned pharmaceutical company, announced the details of a $184 million U.S. expansion plan, including the development of a new R&D center and advanced manufacturing and packaging facility that will serve as the U.S. headquarters for Apotex Corp. and the U.S. offices for Apobiologix. This move marks the largest investment that Apotex has made in the U.S. and will result in at least 150 new full-time positions.

[Read More]